32
Participants
Start Date
January 6, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
August 31, 2026
Sacituzumab Govitecan
Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
RECRUITING
Cleveland Clinic Taussig Cancer Center, Cleveland
RECRUITING
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio
RECRUITING
Texas Oncology Austin, Austin
The University of Texas Health Science Center at San Antonio
OTHER